80 FR 60160 - National Heart, Lung, and Blood Institute; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 192 (October 5, 2015)

Page Range		60160-60160
FR Document		2015-25266

Federal Register, Volume 80 Issue 192 (Monday, October 5, 2015)

[Federal Register Volume 80, Number 192 (Monday, October 5, 2015)]
[Notices]
[Page 60160]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-25266]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Sleep Disorders Research Advisory Board.
    The meeting will be open to the public and conducted 
electronically. The public is encouraged to observe the meeting, and 
should request instructions from the Contact Person listed below in 
advance.

    Name of Committee: Sleep Disorders Research Advisory Board.
    Date: October 9, 2015.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To discuss plans for the proposed revision of the NIH 
Sleep Disorders Research Plan, and potential directions for inter-
agency coordination activities.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Michael J. Twery, Ph.D., Director, National 
Center on Sleep Disorders Research, Division of Lung Diseases, 
National Heart, Lung, and Blood Institute, National Institutes of 
Health, 6701 Rockledge Drive, Suite 10038, Bethesda, MD 20892-7952, 
301-435-0199 twerym@nhlbi.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to internal discussions regarding agenda and scheduling 
details.
    Information is also available on the Institute's/Center's home 
page: http://www.nhlbi.nih.gov/about/committees, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: September 30, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-25266 Filed 10-2-15; 8:45 am]
 BILLING CODE 4140-01-P

60160 Federal Register / Vol. 80, No. 192 / Monday, October 5, 2015 / Notices

Cannabinoid Receptor 1 (CB1) Inverse • HHS Reference No. E–282–2012/0– Place: National Institutes of Health, 6701
Agonists for the Treatment of Diabetes, CA–04—Canadian Patent Application Rockledge Drive, Bethesda, MD 20892
Obesity and Their Complications No. 2889697 filed April 27, 2015 (Virtual Meeting).
Contact Person: Michael J. Twery, Ph.D.,
Description of Technology: • HHS Reference No. E–282–2012/0–
Director, National Center on Sleep Disorders
Cannabinoid (CB1 and CB2) receptors EP–05—European Patent Application Research, Division of Lung Diseases, National
recognize and mediate the effects of the No. 13802153.0 filed June 01, 2015 Heart, Lung, and Blood Institute, National
active compound tetrahydrocannabinol • HHS Reference No. E–282–2012/0– Institutes of Health, 6701 Rockledge Drive,
found in marijuana. CB1 receptor IN–06—Indian Patent Application No. Suite 10038, Bethesda, MD 20892–7952, 301–
activation plays a key role in appetitive 3733/DELNP/2015 filed May 01, 2015 435–0199 twerym@nhlbi.nih.gov.
behavior and metabolism. • HHS Reference No. E–282–2012/0– This notice is being published less than 15
JP–07—Japanese Patent Application No. days prior to the meeting due to internal
Dr. Kunos and colleagues have discussions regarding agenda and scheduling
designed a set of CB1 receptor inverse 2015–542015 filed May 11, 2015
details.
agonists that are effective at reducing • HHS Reference No. E–282–2012/0– Information is also available on the
obesity and its associated metabolic CN–08—Chinese Patent Application No. Institute’s/Center’s home page: http://
consequences while not causing the 201380069389.9 filed July 3, 2015 www.nhlbi.nih.gov/about/committees, where
adverse neuropsychotropic side effects • HHS Reference No. E–282–2012/1– an agenda and any additional information for
linked to earlier antagonists such as US–01—US Provisional Application No. the meeting will be posted when available.
rimonabant. The CB1 receptor 62/171, 179 filed June 04, 2015 (Catalogue of Federal Domestic Assistance
compounds were developed with the Licensing Contact: Jasmine Yang, Program Nos. 93.233, National Center for
goals of (1) limiting their brain Ph.D.; 301–451–7836; jasmine.yang@ Sleep Disorders Research; 93.837, Heart and
penetrance without losing their nih.gov. Vascular Diseases Research; 93.838, Lung
Collaborative Research Opportunity: Diseases Research; 93.839, Blood Diseases
metabolic efficacy due to CB1 inverse and Resources Research, National Institutes
agonism, and (2) generating compounds The National Institute on Alcohol Abuse
and Alcoholism, Laboratory of of Health, HHS)
whose primary metabolite directly
targets enzymes involved in Physiologic Studies, is seeking Dated: September 30, 2015.
inflammatory and fibrotic processes statements of capability or interest from Michelle Trout,
associated with metabolic disorders. parties interested in collaborative Program Analyst, Office of Federal Advisory
The patent application of this research to further develop, evaluate or Committee Policy.
technology are to the composition of commercialize peripherally restricted [FR Doc. 2015–25266 Filed 10–2–15; 8:45 am]
matter and methods of use to the CB1 receptor blockers with improved BILLING CODE 4140–01–P
cannabinoid receptor (CB1) blocking efficacy. For collaboration
compounds for the treatment of obesity, opportunities, please contact George
diabetes, fatty liver disease and a variety Kunos, M.D., Ph.D. at George.Kunos@ DEPARTMENT OF HEALTH AND
of obesity-related metabolic syndromes. nih.gov or 301–443–2069. HUMAN SERVICES
The technology has the potential to be Dated: September 29, 2015.
National Institutes of Health
the next generation of safer CB1 receptor Richard U. Rodriguez,
therapeutics for treating obesity. Acting Director, Office of Technology Center for Scientific Review; Notice of
Potential Commercial Applications: Transfer, National Institutes of Health. Closed Meetings
• Treatment for obesity [FR Doc. 2015–25197 Filed 10–2–15; 8:45 am]
• Treatment for metabolic syndrome BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
• Treatment of diabetes Federal Advisory Committee Act, as
• Treatment of fibrosis amended (5 U.S.C. App.), notice is
• Treatment of Fatty Liver Disease DEPARTMENT OF HEALTH AND hereby given of the following meetings.
such as Nonalcoholic steatohepatitis HUMAN SERVICES The meetings will be closed to the
(NASH) public in accordance with the
Competitive Advantages: National Institutes of Health provisions set forth in sections
• Inhibits metabolic activity without 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
causing psychiatric side effects National Heart, Lung, and Blood as amended. The grant applications and
• Offers improved anti-inflammatory Institute; Notice of Meeting the discussions could disclose
and anti-fibrotic efficacy confidential trade secrets or commercial
Pursuant to section 10(a) of the
Development Stage: property such as patentable material,
Federal Advisory Committee Act, as
• In vitro data available amended (5 U.S.C. App.), notice is
and personal information concerning
• In vivo data available (animal) hereby given of a meeting of the Sleep
individuals associated with the grant
Inventors: George Kunos (NIAAA), applications, the disclosure of which
Disorders Research Advisory Board.
Malliga Iyer (NIAAA), Resat Cinar would constitute a clearly unwarranted
The meeting will be open to the
(NIAAA), Kenner Rice (NIDA) invasion of personal privacy.
public and conducted electronically.
Intellectual Property: The public is encouraged to observe the Name of Committee: Center for Scientific
• HHS Reference No. E–282–2012/0– meeting, and should request Review Special Emphasis Panel; Member
US–01—US Provisional Patent instructions from the Contact Person Conflict: Cognition and Memory.
Application No. 61/725,949 filed Date: October 30, 2015.
listed below in advance. Time: 2:00 p.m. to 4:00 p.m.
mstockstill on DSK4VPTVN1PROD with NOTICES

November 13, 2012
• HHS Reference No. E–282–2012/0– Name of Committee: Sleep Disorders Agenda: To review and evaluate grant
Research Advisory Board. applications.
PCT–02—PCT Application No. PCT/
Date: October 9, 2015. Place: National Institutes of Health, 6701
US2013/069686 filed November 12, Time: 1:00 p.m. to 3:00 p.m. Rockledge Drive, Bethesda, MD 20892
2013 Agenda: To discuss plans for the proposed (Virtual Meeting).
• HHS Reference No. E–282–2012/0– revision of the NIH Sleep Disorders Research Contact Person: Wind Cowles, Ph.D.,
US–03—US Patent Application No. 14/ Plan, and potential directions for inter- Scientific Review Officer, Center for
442,383 filed May 12, 2015 agency coordination activities. Scientific Review, National Institutes of

VerDate Sep<11>2014 18:34 Oct 02, 2015 Jkt 238001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\05OCN1.SGM 05OCN1

Document Created: 2015-12-15 08:52:28
Document Modified: 2015-12-15 08:52:28

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 9, 2015.
FR Citation		80 FR 60160

80 FR 60160 - National Heart, Lung, and Blood Institute; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 192 (October 5, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health